His grandfather didn't hand him a toolbox. He handed him books hidden inside one. The first-generation immigrant from County Cork, Ireland quietly swapped the tools for texts, betting that knowledge would outlast labor. It did. The grandson would grow up to lead 1,100 biotechnology companies in 30 countries, testify before the U.S. Senate, and serve as the living argument that American innovation is the only real national security strategy worth having.
John Francis Crowley was born on April 7, 1967, in Englewood, New Jersey - Bergen County, where the apartment complex held not just his family but grandparents, aunts, uncles, and cousins on both sides. His father was a police officer. His mother was a secretary and waitress. Catholicism was structural, not decorative. The motto his father left him was six words: "Do right, and fear no man." He has been living inside that sentence ever since.
The Education of an Unlikely Executive
He started at the United States Naval Academy. Left after about 18 months. Landed at Georgetown's School of Foreign Service on scholarship, graduating in 1989 with a degree in International Economics. Then Notre Dame Law School - he would later joke that he barely passed contracts. Then consulting. Then Bristol-Myers Squibb, where a company plaque reading "Our mission is to extend and enhance human life" made a different kind of impression than most corporate mission statements do. He went back to school one more time: Harvard Business School, MBA, 1997.
Three elite degrees, the better part of a decade in law and consulting, a pharmaceutical company with global reach - and then, at thirty-three, he put his house on the line.
The $100,000 Bet
In 2000, Crowley left Bristol-Myers Squibb and co-founded Novazyme Pharmaceuticals in Oklahoma City with glycobiologist Dr. William Canfield. The initial capitalization: a $100,000 home equity loan and maxed credit cards. The scientific mission: develop an enzyme replacement therapy for a rare fatal neuromuscular disorder that had devastated his family. The business plan: find investors fast, build a team faster, and do not stop moving.
What followed was one of the most compressed growth arcs in recent biotech history. A $1 million angel round. Then $27 million in venture capital. From startup to 100-plus employees in under 18 months. In 2001, Genzyme Corporation acquired Novazyme for approximately $175 to $200 million. Crowley joined Genzyme as Senior Vice President, leading the global rare disease drug development program. By January 2003, the therapy developed through that work - enzyme replacement treatment now known as Myozyme and Lumizyme - reached patients.
Building Amicus - From Five People to Five Hundred
After Genzyme, Crowley co-founded Amicus Therapeutics in 2005. Five people. A mission focused on rare metabolic diseases. No approved products. He would lead the company for nearly two decades, building it into a global biopharmaceutical organization with 500-plus employees operating in 25 countries.
"Every employee at Amicus is a passionate entrepreneur... We have to be nimble, roll up our sleeves, and resist being constrained by prior thinking." - John F. Crowley, Amicus Therapeutics
In 2018, the FDA approved Galafold (migalastat) for Fabry disease - the first oral therapy for the condition. Getting there was not straightforward. The FDA had initially requested an entirely new clinical trial. Crowley's daughter Megan sat in the First Lady's box at President Trump's first address to a joint session of Congress in February 2017, where Trump mentioned her by name while calling for reduced regulatory barriers. Later that year, the FDA reversed course on Galafold. Crowley stated publicly that he did not believe politics influenced the scientific decision; regardless, the approval came through.
In September 2023, the FDA approved Pombiliti + Opfolda (cipaglucosidase alfa + miglustat) - the first two-component therapy for eligible adults with late-onset Pompe disease. It was the second major FDA approval on Crowley's watch at Amicus, and a signal that the company he built had made good on its original promise.
The Deployment No One Saw Coming
While serving as CEO of publicly traded Amicus Therapeutics, Crowley also maintained a commission in the U.S. Navy Reserve as an intelligence officer. In 2011, he deployed to Afghanistan as Deputy Chief of Intelligence for an elite special operations task force. He worked alongside JSOC, Naval Special Warfare Development Group, and the CIA. He returned. Then went back to the office.
"I had a chance to work with some of the greatest warriors in the history of the world." - John F. Crowley, on his 2011 Afghanistan deployment
This is the part of Crowley's biography that tends to stop people mid-sentence. Running a biotech company while serving in Afghanistan is not a dual identity most executives carry. It is, however, consistent with the rest of his career - a pattern of refusing to let any single identity be the whole story.
Taking the Helm at BIO
On March 4, 2024, Crowley became President and CEO of the Biotechnology Innovation Organization - BIO - the world's largest biotech trade association. His mandate was clear. The industry was fragmented on social issues, bruised by political battles, and losing the narrative on China. He arrived with a framework he calls "man-made problems": regulatory, legislative, and policy barriers that slow the development of life-saving therapies.
"The primary bottleneck stifling biotechnology is no longer a deficit of scientific imagination, but rather the archaic, man-made operational infrastructure surrounding translation." - John F. Crowley, BIO
His agenda at BIO is specific and loud. FDA Modernization: he has endorsed "Project Trailblazer," pushed for expanded single Institutional Review Board policies, and pressed for faster first-cycle drug reviews. Currently only 56% of standard applications get first-cycle approval - a number he treats as a systemic failure, not a baseline.
On China: he regularly cites that China now accounts for 30% of global clinical trial starts (versus the U.S. at 35%), and that China's share of the global biopharma pipeline rose from 4% to 32% in one decade. His position is not restriction but competition. "I do worry about unintended consequences and effectiveness of trying to put bans in place," he told GeneOnline. "You worry about, frankly, distraction from the real issues, which is, how do we outcompete?"
In May 2025, when the Trump administration proposed Most Favored Nation drug pricing, Crowley called it "a deeply flawed proposal that would devastate our nation's small- and mid-size biotech companies." In September 2025, he warned that immediate 100% pharmaceutical tariffs would harm public health and national security. In October 2025, he testified before the Senate HELP Committee. The testimony opened with his family's personal story - not as preamble, but as argument.
BIO 2026: The 50th Anniversary Speech
In June 2026, Crowley headlined the BIO International Convention in San Diego - biotech's 50th anniversary gathering, roughly 20,000 attendees. He spoke about AI democratization across companies of all sizes, clinical trial modernization, and what he now calls "inescapable dependencies" that the U.S. cannot afford to build into its biotech supply chain. The speech was covered in Genetic Engineering & Biotechnology News and BioSpace as a marker of where the industry's de facto spokesperson stands.
"The world is a better, safer, healthier, and more prosperous place when the United States and its allies continue to lead in biotechnology." - John F. Crowley, BIO International Convention 2026
Notre Dame, a Grandchild, and the Long View
He was named Notre Dame's 2020 commencement speaker. COVID moved the ceremony to May 2022. In the address, he told graduates: "God brought you here to Notre Dame years ago, not to provide you a path to an easy life... God brought you to Notre Dame to do difficult things." He also announced that his first grandchild was expected within two weeks. Stella Aileen Crowley was born June 18, 2022 - Father's Day weekend.
Notre Dame gave him an Honorary Doctor of Laws that same day. He joked about barely passing contracts in law school three decades earlier. The same institution that once let him squeak by handed him its highest academic honor. It is the kind of closing line that writes itself - and Crowley, who has been telling his own story for long enough to know which details land, let the moment speak.
"All we really are pursuing is time - time with the people we love." - John F. Crowley, Notre Dame Commencement Address, 2022
The Operating Philosophy
Crowley speaks on a circuit that spans biotech conventions, rare disease summits, military associations, and university commencements. His speaking topics include "Never, Never, Never Quit" and "The Future of U.S. Biotechnology and Global Competitiveness" - the range reflects the range of the man. Audience testimonials mention standing ovations at a Madison, Wisconsin Civics Club alongside Senate committee rooms.
His advocacy is deliberately bipartisan by design. "There's no left, there's no right, there's only back or forward." He sits on the University of Notre Dame Board of Trustees and the United States Naval Academy Foundation Board. He was a founding board member of the Global Genes Project, and served as National Chairman of Make-A-Wish Foundation of America in 2014. He led the formation of the Congressional Caucus on Rare Diseases in 2010.
He received the Ernst & Young New Jersey Entrepreneur of the Year award in 2007. The Henry Crown Fellowship at the Aspen Institute in 2009. The Hubert J.P. Schoemaker Leadership Award from Life Sciences PA in April 2024 - weeks after taking the BIO job. In 2023, he was inducted into the Horatio Alger Association of Distinguished Americans, which honors those who have overcome adversity to achieve significant professional success.
"For years people said we were on the cusp of a golden age of medicine. I believe we are living in it now." - John F. Crowley
His grandfather bet on books over tools and won. Crowley has been making that same bet, at larger and larger scale, ever since. Today the bet has an address: 1201 New York Ave NW, Washington, DC - where the Biotechnology Innovation Organization and its new CEO are arguing, loudly and specifically, that the U.S. cannot afford to stop winning this one.